Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Vermeire S, Peyrin-Biroulet L, Panés J, Regueiro M, Kotze PG, Charabaty A, Goetsch M, Shan K, Wu J, McDonnell A, Woolcott JC, Danese S May 9, 2023 DDW May 2023 Ulcerative Colitis

Etrasimod for the Treatment of Ulcerative Colitis: Up to 2.5 Years of Pooled Safety Data From Global Clinical Trials

View Presentation
Oral Presentation
D’Haens G, Dubinsky MC, Peyrin-Biroulet L, Danese S, Sands BE, Wolf DC, Yarur A, Chiorean M, Dray D, Modesto I, Tan H, Gu G, Lopez C, Su C, Zhang J, Cataldi F, McDonnell A, Schreiber S, Feagan BG, Vermeire S May 9, 2023 DDW May 2023 Inflammatory Bowel Disease

Etrasimod Induction Therapy in Moderately to Severely Active Crohn’s Disease: Results From a Phase 2, Randomised, Double-Blind Substudy

View Presentation
Poster
Armuzzi A, Rubin DT, Schreiber S, Panés J, Fellmann M, Bartolome L, Goetsch M, Bhattacharjee A, Wu J, Chaparro M, Dubinsky MC May 9, 2023 DDW May 2023 Ulcerative Colitis

Health-Related Quality of Life From the Inflammatory Bowel Disease Questionnaire in Patients With Ulcerative Colitis Treated With Etrasimod in the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Sands BE, * Vermeire S, * Dubinsky MC, Feagan BG, Panaccione R, Jairath V, Yarur AJ, Chiorean MV, Panés J, Goetsch M, Rabbat CJ, Shah P, Wu J, Ghosh S May 9, 2023 DDW May 2023 Ulcerative Colitis

Maintenance of Week 12 Responses Through Week 52 With Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the Phase 3 Elevate UC 52 Trial

View Presentation
Poster
Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR May 9, 2023 DDW May 2023 Ulcerative Colitis

One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

View Presentation
Poster
Rubin DT, Panés J, Torres J, Kobayashi T, Su C, Lawendy N, Modesto I, Segovia M, Gardiner S, Wang W, Vermeire S May 9, 2023 DDW May 2023 Ulcerative Colitis

Treatment Outcome of Tofacitinib Dose Reduction to 5 MG Twice Daily (BID) vs Remaining on 10 MG BID in Patients With Ulcerative Colitis Who Were in Stable Remission on 10 MG BID: Updated 30 Month Data From the Double-Blind, Randomized Riveting Study

View Presentation